TOGETHER, WE’RE MAKING A
DIFFERENCE IN CANCER TREATMENT
The treatment landscape is changing almost daily and we’re at the forefront with our innovative therapies and a robust pipeline. Our collaborations, research, and support are leading to exciting new discoveries and an amplified sense of hope for patients.
WHO We ARE
Headquartered in New Jersey, we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for millions of patients in need. Our lead asset Plinabulin is being developed as a “pipeline in a drug” in multiple cancer indications, including NSCLC and SCLC.
We are an equity owner of SEED Therapeutics, which is a leading Targeted Protein Degradation (TPD) 2.0 company focusing on developing novel “molecular glues” for breakthrough therapeutics. We remain part of SEED’s continued success in revolutionizing drug discovery.
PIPELINE & RESEARCH
Cancer is relentless—but so are we. Our promise is to be your persistent partner in improving outcomes and outlooks with our advanced immunotherapies and continuous product development.
NEWS & MEDIA
From product development updates to corporate news, find the latest right here.